Joshua P. Cohen, PhD
Research Associate Professor
Area of Expertise
Prescription drug reimbursement policy, drug formulary trends, comparative effectiveness research, prescription-to-over-the-counter switching
|Faculty Summary||Recently Completed Research Projects|
Dr. Joshua Cohen utilizes his background in health economics to examine public policy issues that concern prescription drug reimbursement and market access. His areas of research include pharmacy benefits management as it relates to the Medicare prescription drug benefit, formulary regulations established by the Centers for Medicare and Medicaid Services, ethics and the distribution of pharmaceutical care resources, comparative effectiveness research, market access to biopharmaceuticals in the US and Europe, role of clinical and cost-effectiveness in clinical practice guideline development, drug development targeting neglected diseases, and decisions by drug regulatory agencies regarding prescription (Rx) to over-the-counter (OTC) switches.
Current Research Initiatives
- Patient access to newly approved oncology drugs in US and Europe
- Clinical, regulatory, and economic challenges facing pharmacogenomics
- Prescription-to-over-the-counter switches in US and Europe
- Trends in biosimilar market uptake
- Cohen, J. Dearth of clinically useful diagnostics limits growth of personalized medicine. Expert Review of Clinical Pharmacology 2011; 4(5):527-529.
- Wilson A, Cohen J. Comparing access to cancer drugs in US and Australia. Value in Health 2011; 14(6): 244-252.
- Cohen J, Wilson A, Manzolillo K. Clinical and economic challenges facing pharmacogenomics. Pharmacogenomics Journal. doi:10.1038/tpj.2011.63.
- Cohen J, Christensen K, Feldman L. Role of disease management in patient compliance. Population Health Management 2012; 15(1): 20-28. doi:10.1089/pop.2011.0020.
- Cohen J, Looney W. Response to Fojo and Grady, How much is life worth? The $440 billion question. Journal of the National Cancer Institute 2010: doi: 10.1093/jnci/djq246
- Cohen J, Looney W. Impact of comparative effectiveness research on cancer care. Nature Biotechnology 2010; 28:1160-1163.
- Cohen J, Dibner M, Wilson A. development of and access to products for neglected diseases. PLoS ONE 2010; 5(5): e10610. doi:10.1371/journal.pone.0010610
- Cohen J, Bridges J. Assessing comparative effectiveness research in the US. Applied Health Economics and Health Policy 2009; 7(4):219-224.
- Cohen J, Wilson A. Off-label use reimbursement. Food and Drug Law Journal 2009; 64(2): 391-403.
- Cohen J, Stolk E, Niezen M. Role of budget impact in drug reimbursement decisions: The increasingly complex fourth hurdle. Journal of Health Politics, Policy, and Law 2008, Apr:33(2): 225-242.
- Cohen J,Young B Rochon S Faden L. Are Medicare plans complying with CMS regulation? Expert Review of Pharmacoeconomics & Outcomes Research 2008 Apr;8(2): 133-139.
- Cohen J Stolk E Niezen M. The increasingly complex fourth hurdle for pharmaceuticals, Pharmacoeconomics 2007;25(9): 727-734.
- Cohen J, Paquette C, Cairns C. Can Medicare draw lessons from Dutch experience with a national formulary, Drug Information Journal 2007;41(2): 257-272.
- Cohen J, Faden L, Predaris S, Young B. Patient access to pharmaceuticals: an international comparison, European Journal of Health Economics 2007;8(3): 253-266.
- Cohen J, Cairns C, Paquette C, Faden L. Comparing patient access to pharmaceuticals in the UK and US, Applied Health Economics and Health Policy 2006;5(3): 177-187.
|Teaching||Board Memberships and Affiliations|